Standard BioTools Inc.

NASDAQ:LAB

Medical - Devices

Healthcare
$0.57 +3.38%

+$0.03 today

Market cap
$225.03M
Beta
1.38
P/E (TTM)
-3.5
EPS (TTM)
-$0.24
52W Low $0.79High $1.72

Volume 0.70M

Average 2.91M

LAB Common Stock Issued

Cash raised by issuing new shares.

Standard BioTools Inc.NASDAQ: LAB

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued outflow grows to $78K

Q1 FY2026 common stock issued was $78K, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $824K.

Context

  • Common stock issued amounted to 1.2% of revenue in FY2025, up 1.2 pp from a year earlier.
  • Common stock issued increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock issued holds near $78K or moves back toward the trailing-twelve-month quarterly average of $206K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$78K-89.5% QoQ
Last fiscal yearDec 2025
$1.05M— YoY
LTMMar 2026
$824K+1111.8% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
1.05M USD
Year-over-year change
—

Common Stock Issued vs competitors

How LAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1111.8% is the 2nd highest of 5, against a peer median of -5.4%.
  • Common stock issued amounts to 1.0% of revenue for LAB, versus a peer median of 0.4%.
LAB Competitors
Common Stock Issued for LAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ADCTADC Therapeutics S.A.LTM Mar 2026$59.25M USD+4936.3%—74.8%
CBLLCeriBell, Inc.LTM Mar 2026$6.92M USD——7.3%
VREXVarex Imaging CorporationLTM Apr 2026$3.3M USD——0.4%
BVSBioventus Inc.LTM Mar 2026$2.04M USD-15.4%-29.1%0.4%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$1.47M USD-99.5%-49.4%—
CTKBCytek Biosciences, Inc.LTM Mar 2026$1.32M USD—-19.1%0.6%
LABStandard BioTools Inc.LTM Mar 2026$824K USD+1111.8%—1.0%
AVNSAvanos Medical, Inc.LTM Mar 2026$700K USD——0.1%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$518K USD+4.6%-37.0%0.2%
SYSo-Young International Inc.LTM Dec 2025CN¥79K CNY——0.0%
KIDSOrthoPediatrics Corp.LTM Mar 2026$0 USD——0.0%
Peer median (excluding LAB) —-5.4%-33.1%0.4%

Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(59.24M)(190.1M)(74.66M)(138.89M)(74.9M)
Depreciation & Amortization16.2M15.03M15.18M16.86M1.72M
Deferred Income Tax00000
Stock-Based Compensation16.1M14.88M13.12M31.73M29.61M
Change in Working Capital(18.01M)(12.35M)1.79M(12.08M)(44.98M)
Accounts Receivables6.73M1.06M(2.99M)8.97M(1.36M)
Inventory(4.78M)(8.47M)(4.91M)(9.88M)(11.52M)
Accounts Payables001.62M02.44M
Other Working Capital(19.95M)(4.95M)8.07M(11.17M)(34.53M)
Other Non-Cash Items886K83.17M1.28M(41.08M)14.2M
Operating Cash Flow(44.06M)(89.37M)(43.29M)(143.45M)(74.35M)
Capital Expenditures(13.26M)(3.83M)(2.83M)(8.36M)(8.3M)
Acquisitions (Net)000278.65M0
Purchases of Investments00(94.9M)0(140.93M)
Sales of Investments00117.96M0179M
Other Investing Activities1.32M(84.3M)092.88M(5M)
Investing Cash Flow(11.95M)(88.13M)20.24M363.17M24.77M
Debt Repayment9.5M18.16M(2.08M)(63.19M)0
Common Stock Issued00001.05M
Common Stock Repurchased(1.79M)(774K)(5.41M)(40.95M)0
Dividends Paid00000
Other Financing Activities8.25M213.37M827K1.53M(484K)
Financing Cash Flow15.96M230.76M(6.81M)(102.62M)570K
Effect of Forex Changes(21K)(404K)34K(785K)842K
Net Change in Cash(40.07M)52.86M(29.83M)116.32M(48.17M)
Free Cash Flow(57.33M)(93.2M)(46.12M)(151.81M)(82.65M)

Standard BioTools Inc.

NASDAQ:LAB

Intrinsic Alpha fair value

Locked

Current Price

$0.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.